Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed in Patients With Advanced Solid Tumors

NCT00743379 is registered in ClinicalTrials.gov with Threshold Pharmaceuticals as lead sponsor.

NCT NCT00743379
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00743379 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed in Patients With Advanced Solid Tumors
Lead sponsor
Threshold Pharmaceuticals
Phase
Phase 1/2
Overall status
Completed
Start date
August 31, 2008
Completion date
March 31, 2014
Enrollment
71 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer, pancreatic cancer, prostate cancer